Well, we have come down to test the most base support. The 10-k was very doom and gloom but it also said they allowed MAXM to buy 8%. the CEO and insiders still own a huge chunk of this company. I got in suspecting a buyout and this 10-k has only made me a little more confident that a major pharma company will be buying and marketing this new drug. The only down side I could see is the fact each treatment is individualized based on the patient. That also makes IMUC unique. Just like the 10-k said, if IMUC doesn't get bought out consider this a waste of money. If they do, it's because their phase three trial was approved and this little piggy went to the market.

Trade well, DMWcrash